Combining low dose craniospinal irradiation with focal radiotherapy for children with WNT medulloblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study focuses on treating children diagnosed with WNT pathway medulloblastoma, a type of brain tumor known for its favorable prognosis. The approach involves administering low dose craniospinal irradiation alongside focal radiotherapy, aiming to reduce long-term side effects associated with higher radiation doses while maintaining effective disease control. The study seeks to evaluate the safety and efficacy of this de-intensified treatment strategy in newly diagnosed patients. By carefully selecting participants based on specific eligibility criteria, the study aims to optimize treatment outcomes for this low-risk group.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age more than 3 years and less than 16 years.
* Newly diagnosed WNT pathway medulloblastoma.
* Post-surgery residual disease less than 1.5 cm2 on post-operative MRI brain.
* No evidence of metastatic disease in the brain, spine or cerebral spinal fluid (CSF) assessed by MRI of the brain/spine and lumbar puncture for CSF cytology.
* Fit for initiation of adjuvant treatment within 6-weeks of surgery

Exclusion Criteria:

* Age Less than 3 and more than 16 years.
* Molecular subgroup other than WNT pathway.
* Post-surgery residual disease more than 1.5cm2 on post-operative imaging.
* Evidence of any metastatic disease in the brain, spine or CSF.
* Previous history of radiotherapy or chemotherapy prior to study enrollment.
* Not fit for initiation of adjuvant treatment within 6 weeks of surgery.
* Not willing for consent/assent.

Where it's running

• Tata Memorial Hospital
  Mumbai, Maharashtra, India Recruiting

Study contacts

• Study coordinator: Tejpal Dr Gupta, MD
• Email: tejpalgupta@rediffmail.com
• Phone: (022) 2417 6015

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using digoxin to treat relapsed medulloblastoma in young patients

  This study is testing if digoxin can help young patients with relapsed medulloblastoma feel better when other treatments have not worked.

  Recruiting at 17 sites Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Birmingham, Alabama and 17 other locations · NCT06701812

• Combining T Cell Therapy and Vaccines with Immune Blockade for Medulloblastoma

  This study is testing a new treatment that combines special immune cell therapy and vaccines to see if it can help children and young adults with recurring medulloblastoma feel better.

  Recruiting Phase 1 University of Florida · Washington D.C., District of Columbia and 1 other locations · NCT06514898

• Registry for relapsed or progressive SHH medulloblastoma with U1 mutation

  This registry collects medical records and biological samples from people aged 3–50 with relapsed or progressive SHH medulloblastoma to test for U1 mutations and create a biobank for research.

  Recruiting at 2 sites Baylor College of Medicine · Houston, Texas and 1 other locations · NCT07242963

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.